Autologous Hematopoietic Stem Cell Transplantation for Patients With Multiple Myeloma

Primary Central Nervous System Lymphoma: Treatment and Nursing Management of Immunocompetent Patients

BACKGROUND

Primary central nervous system lymphoma (PCNSL) is a rare primary brain tumor. Because of its rarity and the increasing incidence rates as the U.S. population ages, it is important for nurses to understand the unique needs of patients and their caregivers during the disease continuum.

OBJECTIVES

This article provides an overview of the treatment and nursing management of immunocompetent patients with PCNSL.

METHODS

An extensive examination of the current literature, including incidence, diagnosis, treatment, and implications for nursing, was performed.

FINDINGS

Nurses play a vital role in caring for patients with PCNSL and addressing their unique needs. Nurses should concentrate on early recognition and comprehensive management of neurologic symptoms. This includes patient and caregiver education and diligent implementation of treatment strategies, as well as maximizing quality of life.

Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients

OBJECTIVE

To review the current evidence on strategies for selecting the optimal treatment for newly diagnosed patients with multiple myeloma (MM).

DATA SOURCES

Journal articles, research reports, state of the science papers, and clinical practice guidelines.

CONCLUSION

Despite the plethora of drugs to effectively treat MM, the optimal induction regimen for patients with newly diagnosed MM is unknown. Rapid control of the disease, appropriate treatment selection and effective supportive care strategies remain integral to prevention and management of the disease. Strategies for selecting the optimal treatment include considering inherent patient characteristics, frailty, and existing clinical practice guidelines.

IMPLICATIONS FOR NURSING PRACTICE

Nurses should provide patients with disease- and treatment-related education to enhance patient and caregiver understanding of the disease and treatment options, taking into consideration clinical data and overarching goals of treatment.

Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma

OBJECTIVE

To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM).

DATA SOURCES

Journal articles, research reports, state of the science papers, and clinical guidelines.

CONCLUSION

There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens.

IMPLICATIONS FOR NURSING PRACTICE

With these advances in the therapeutic landscape, knowledge of these drugs, side effects and nursing implications are essential to improve outcomes. Patient education is also of vital importance in achieving optimal responses to treatment.